Misplaced Pages

This is an old revision of this page, as edited by Buidhe (talk | contribs) at 20:47, 1 December 2023 (Moving from Category:Experimental drugs to Category:Experimental monoclonal antibodies using Cat-a-lot). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.

Ponezumab was developed by Pfizer Inc. In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial.

References

1. "Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.
2. Popescu CD, Trofin D, Ignat B, Matei D (2014). "New Aspects of Therapeutic Management in Alzheimer`s Disease". In Atta-ur-Rahman (ed.). Frontiers in Clinical Drug Research: Alzheimer Disorders. Vol. 3. Sharjah: Bentham Science Publishers. p. 55. doi:10.2174/9781681080680115030004. ISBN 978-1-68108-068-0.
3. "Alzforum".

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Pfizer brands
• Anti-amyloid monoclonal antibodies
• Experimental monoclonal antibodies
• Monoclonal antibody stubs
• Nervous system drug stubs